Cyrano’s Phase II trial of CYR-064 meets primary safety endpoint

Phase 2positiveCYR-064Positive

AI Analysis

Summary

Cyrano Therapeutics reported that its Phase II FLAVOR study of CYR-064 met its primary safety endpoint in patients with hyposmia. The article provides no efficacy data or patient numbers.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Phase II FLAVOR study met its primary safety endpoint; no efficacy results stated in the article.

Importance:5/10

Sentiment:

0.40

phase_2clinical_trialsafety_endpointhyposmiaprivate_company

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 19, 2026 7:27 AM

Read Original